Novel GLP-1 Pill for Obesity Passes Phase III Test

(MedPage Today) — An investigational small-molecule, nonpeptide oral GLP-1 receptor agonist significantly reduced weight in adults with obesity in the randomized ATTAIN-1 trial.
At week 72, orforglipron at multiple doses proved superior to placebo…